Percutaneous thrombectomy for the treatment of venous thromboembolism | Abbott
CARDIOVASCULAR
hamburger
JETi

Percutaneous thrombectomy with the JETi™ Peripheral Thrombectomy System for the treatment of venous thrombosis

Overview: Retrospective Study

Cournoyer-Rodrigue et al., JVIR. 2019.

Background
Mechanical and pharmacomechanical based thrombectomy may improve clinical outcomes, reduce concomitant CDT and lessen need for intensive care unit stays compared to anticoagulation alone.

Objective
To evaluate the safety and efficacy of JETi™ Thrombectomy System in treating acute venous thrombosis.

Method
Retrospective evaluation of 18 consecutive patients with 21 instances of acute venous thrombosis in JETi™ Thrombectomy System new user facility.

Primary Endpoints
Technical Success Rate (restoration of antegrade flow with or without additional treatment of an underlying obstructive lesion) and Procedural Success Rate (technical success with or without the addition of overnight CDT).

Clinical Outcomes

The JETi™ Peripheral Thrombectomy System achieved a 100% procedural success rate in 18 consecutive patients with a wide variety of target treatment vessels and had ZERO reports of blood transfusions, hypotension or hemolysis..

  Procedural Success Rate Single-Session Clot Reduction Overall Clot Reduction
(Single-Session + Overnight CDT)
Iliofemoral Vein (n=9) 100% 81% 96%
Axillosubclavian Vein (n=10) 100% 100% 100%
Portal Vein (n=2) 100% 100% 100%

*5 patients required overnight CDT.

JETi™ achieved a 100% procedural success rate in a wide variety of target treatment vessels at a brand-new JETi™ user facility.

100%

JETi™ can achieve successful venous thrombectomy without overnight catheter directed thrombolysis in most patients.

Success

Reducing the need for overnight thrombolytics can lessen utilization of hospital resources and decrease intensive care unit stays resulting in lower costs compared with CDT.

Lower cost

Reference:

Cournoyer-Rodrigue et al., JVIR. 2019.

Important Safety Information
Request a Demo

MAT-2205000 v1.0

IMPORTANT SAFETY INFORMATION

rx-only-logo  JETi™ All-In-One Peripheral Thrombectomy System


Indications

The JETi™ AIO Peripheral Thrombectomy System is intended to remove/aspirate fluid and break-up soft emboli and thrombus from the peripheral vasculature and to sub selectively infuse/deliver diagnostics or therapeutics with or without vessel occlusion.
 

Contraindications

The JETi™ AIO Peripheral Thrombectomy System is contraindicated for use in:

  • Vessels smaller than 4 mm (0.16”)
  • Coronary, pulmonary, and neurovasculature


Warnings

The JETi™ Peripheral Catheter, JETi™ AIO Suction Tubing, and JETi™ Pump Set contents are supplied sterile using EO. Do not use if the expiration date has passed or the sterile barrier is damaged.

  • The JETi™ Peripheral Catheter, JETi™ AIO Suction Tubing, JETi™ AIO Non-Sterile Kit, and JETi™ Pump Set contents are for single patient use only. Dispose after use. Do not reuse, reprocess, modify, or resterilize. Reuse, reprocessing, modification, or resterilization may compromise the structural integrity of the device and/or lead to device failure which, may result in patient injury, illness or death. Reuse, reprocessing, or resterilization may also create a risk of contamination of the device and/or cause patient infection or cross-infection, including, but not limited to, the transmission of infectious disease(s) from one patient to another. Contamination of the device may lead to injury, illness, or death of the patient.
  • The JETi™ AIO Peripheral Thrombectomy System is not approved for use with defibrillation. In the event shock must be delivered to the patient, remove the catheter and clear all connected system components from the patient before delivering shock.
  • Do not use a catheter that has been kinked or damaged.
  • Do not use a pump set if it does not prime.
  • Only use the JETi™ Peripheral Catheter and JETi™ AIO Suction Tubing with the JETi™ AIO Peripheral SDU.
  • Do not mix contrast media in the saline bag.
  • When the catheter is exposed to the arterial system, it should be manipulated while under high-quality fluoroscopic observation.
  • In the event that the catheter becomes blocked or clogged with thrombus, remove and replace the device with a new device.
  • Do not use if package is opened or damaged.
  • To avoid risk of electric shock, the SDU must only be connected to mains power with a protective earth.
  • The power socket-outlet must be located near the device and must be easily accessible.
  • Do not modify or alter the device.
  • Do not step or stand on the base of the device.
  • Do not push or lean against the IV pole.


Precautions

Physicians must read and understand the Instructions for Use (IFU) prior to using the device. The device must be used by physicians skilled in percutaneous, intravascular techniques in a fully equipped catheterization laboratory.
 

Potential Adverse Effects

Potential adverse events include, but are not limited to:

  • Acute closure
  • Aneurysm or pseudo aneurysm
  • Allergic reaction to contrast
  • Arrhythmia
  • Death
  • Embolism (air or device)
  • Embolization (thrombotic)
  • Emergency surgery
  • Access site pain, hemorrhage, or hematoma
  • Infection (systemic/sepsis)
  • Local infection (puncture site)
  • Minimal blood loss
  • Vessel dissection, perforation, or other injury
  • Vessel spasm
  • Thrombosis

JETi™ is a trademark of Walk Vascular. Walk Vascular is a subsidiary of the Abbott Group of Companies.
Manufactured by Walk Vascular LLC 17171 Daimler Street, Irvine CA, 92614 USA

MAT-2116195 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.